GENSCRIPT BIO (01548): Prosper received new payment based on the licensing agreement with Lixin Pharmaceutical Technology.

GenScript Bio (01548) announced that it has received a new payment of approximately RMB 480 million (approximately $67.5 million, after deduction of withholding tax) under the re-stated and amended licensing agreement. This payment is the second installment of sublicensing revenue related to the licensed anti-PD-1 single-domain antibody under the re-stated and amended licensing agreement. The anti-PD-1 single-domain antibody is used in the development of LM-299, a new PD-1/VEGF bispecific antibody that has received approval for new drug clinical research. As of October 14, 2025, GenScript Bio has accumulated a total of approximately RMB 2 billion (approximately $284 million, after deduction of withholding tax) under the re-stated and amended licensing agreement. The receipt of these funds will further enhance GenScript Bio's cash reserves and support new molecule discovery and development.